Labcorp (LH) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
10 Apr, 2026Executive summary
Annual Meeting scheduled for May 21, 2026, with voting available online, by phone, mail, or virtually.
Shareholders are encouraged to review proxy materials and vote on key proposals affecting governance and compensation.
Voting matters and shareholder proposals
Election of eleven nominees to the Board of Directors, each recommended for approval.
Advisory (non-binding) vote to approve compensation of Named Executive Officers.
Ratification of Deloitte and Touche LLP as independent auditor for the fiscal year ending December 31, 2026.
Other business may be addressed as appropriate during the meeting.
Board of directors and corporate governance
Eleven individuals nominated for Board positions, including experienced professionals from diverse backgrounds.
Board recommends voting in favor of all director nominees.
Latest events from Labcorp
- 2025 saw record revenues, board refreshment, and strong ESG and pay-for-performance alignment.LH
Proxy filing10 Apr 2026 - 2025 saw 7.2% revenue growth and strong EPS gains, with positive 2026 guidance.LH
Q4 202517 Feb 2026 - Q2 revenue up 6.2% to $3.22B, with higher guidance and expanded capital returns.LH
Q2 20242 Feb 2026 - Growth driven by specialty testing, global expansion, and accretive acquisitions, with raised 2024 guidance.LH
The 44th Annual William Blair Growth Stock Conference31 Jan 2026 - Inorganic growth accelerates, core businesses remain strong, and Invitae integration is on track.LH
Baird's 2024 Global Healthcare Conference21 Jan 2026 - Q3 2024 revenue up 7.4% year-over-year, with strong Diagnostics and Biopharma growth.LH
Q3 202418 Jan 2026 - Specialty testing, M&A, and AI drive growth, with regulatory changes closely monitored.LH
44th Annual J.P. Morgan Healthcare Conference14 Jan 2026 - Strong 2024 growth and strategic focus position the company for continued momentum in 2025.LH
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - Q4 revenue up 9.8% to $3.33B; 2025 guidance targets 6.7–8% growth and higher margins.LH
Q4 20248 Jan 2026